 | | | | | | |||||||||
 | ||||||||||||||
| ||||||||||||||
 | ||||||||||||||
| | |||
 | ||||
As a regular speaker at generic conferences, I have been involved in several new speaking engagements during 2008 and will be undertaking more in the final quarter of 2008. In December, I will be running a half-day seminar in London on behalf of SMi Group entitled Intellectual Property and Generics Masterclass . Intellectual Property, often abbreviated to IP, plays an extremely significant role in the generic world, but not everybody who ought to know about it really understands it. The topic includes important matters such as patent issues and data exclusivity and these two are often confused, even though there are significant differences between them. IP issues can affect generic development, registration and launch and making mistakes due to a lack of knowledge can work out very expensive. Anyone who wants to make progress in the generic world needs to ensure that they have a good understanding of the basic issues, which this half-day seminar is designed to provide. Brochure available from http://www.smi-online.co.uk//events/brochure.asp?is=4&ref=3031 New publications In association with Decision Resources International, Interpharm is pleased to announce the publication of a new report in May 2008 - Asia: Threat or Opportunity? Asian economic might is growing, and the Asian pharmaceutical markets and industry are growing along with it. Western pharmaceutical companies have become very interested in entering Asian markets and taking advantage of the opportunities they offer. Cost cutting alone, however, should not be the sole reason for multinational companies (MNCs) to outsource activities to Southeast Asia. Companies must make the effort to understand the local culture and business environment in each country they want to enter if they are to avoid unrealistic expectations and disappointments. The negative long-term effects could overshadow the benefits of short-term gains. Although Asian markets may prove challenging, they also offer significant opportunities for companies that focus their needs and then execute well-conceived strategies in specific countries. Detailed information about the paper is available on the DRI site January 2008 saw the publication of Indian Generics, 2008-2012: The Growing Threat to Westernised Markets by Interpharm, in association with Spectra Intelligence. More information can be found on the Spectra web site. The report looks at issues such as why India has become such a pharmaceutical force and examines the commercial, strategic and regulatory background to their success. Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world. Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western markets with great success. These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger market shares and increase the levels of competition. Why has this challenge arisen - what advantages do Indian companies enjoy that enable them to compete so successfully with Western generic companies? It is the purpose of this report to answer that question and to provide Western pharmaceutical companies and others that are interested by this phenomenon with some explanation of the background.
Future speaking appearances As a regular speaker at generic conferences, I have been involved in several new speaking engagements during 2008 and will be undertaking more in the final quarter of 2008. In December, I will be running a half-day seminar in London on behalf of SMi Group entitled Intellectual Property and Generics Masterclass . Intellectual Property, often abbreviated to IP, plays an extremely significant role in the generic world, but not everybody who ought to know about it really understands it. The topic includes important matters such as patent issues and data exclusivity and these two are often confused, even though there are significant differences between them. IP issues can affect generic development, registration and launch and making mistakes due to a lack of knowledge can work out very expensive. Anyone who wants to make progress in the generic world needs to ensure that they have a good understanding of the basic issues, which this half-day seminar is designed to provide.
For information about my other published reports, please see the Publications section of About Interpharm. | ||||